Day

June 26, 2020
Background | Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. Methods...
Continue Reading
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have unveiled the first in silico multiple myeloma patient. Called Gemini, the in silico multiple myeloma patient is a computer model of disease progression and drug response at the individual patient level. The company says Gemini has multiple...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand